CIAP2 as a therapeutic target in colorectal cancer and other malignancies

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 11, 2009, Pages 1333-1345

  Miura, Koh ^a   Karasawa, Hideaki ^a   Sasaki, Iwao ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

apoptosis; cIAP2; colorectal cancer; IAP family; therapeutic target

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 1 (2 METHOXYETHYL) 2 METHYL 4,9 DIOXO 3 (PYRAZIN 2 YLMETHYL) 4,9 DIHYDRO 1H NAPHTHO[2,3 D]IMIDAZOLIUM BROMIDE; AEG 35156; AEG 40730; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; DEATH RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLUOROURACIL; FUCOXANTHIN; FUCOXANTHINOL; GATAPARSEN; I KAPPA B; IDRONOXIL; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; LIVIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; RMT 5265; RO 106 9920; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SM 122; SM 164; SM 337; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; BIRC3 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ABSENCE OF SIDE EFFECTS; ADENOMATOUS POLYP; AMINO ACID SEQUENCE; APOPTOSIS; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; COLON CARCINOGENESIS; COLORECTAL CANCER; CYTOPLASM; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; ESOPHAGUS CANCER; EXON; FAMILIAL DISEASE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC CODE; GOLGI COMPLEX; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTONE PHOSPHORYLATION; HUMAN; IC 50; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM CELL; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MICROSATELLITE INSTABILITY; MITOCHONDRION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OVARY CANCER; POLYHEDROSIS VIRUS; PROGNOSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; UBIQUITINATION; ZINC FINGER MOTIF; ANIMAL; COLORECTAL TUMOR; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 73449148422     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728220903277256     Document Type: Review

References (74)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30 (Pubitemid 40310185)
2. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993;306:752-5 (Pubitemid 23080053)
3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fuorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14
4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fuorouracil with or without oxaliplatin as frst-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47 (Pubitemid 30644117)
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 (Pubitemid 38702844)
6. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev 2000;64:821-46 (Pubitemid 32475932)
7. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specifcity, activation and inhibition. Biochem J 2004;384:201-32 (Pubitemid 39656233)
8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21 (Pubitemid 27353455)
9. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007;13:5995-6000 (Pubitemid 350075054)
10. Karasawa H, Miura K, Fujibuchi W, et al. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 2009;100:903-13
11. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12:1543-68 (Pubitemid 47106887)
12. Hinds MG, Norton RS, Vaux DL, Day CL. Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat Struct Biol 1999;6:648-51 (Pubitemid 29318954)
13. Sun C, Cai M, Gunasekera AH, et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP Nature 1999;401:818-22
14. Roy N, Mahadevan MS, McLean M, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995;80:167-78
15. Yang Y, Fang S, Jensen JP, et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874-7 (Pubitemid 30257739)
16. Martin SJ. Dealing the CARDs between life and death. Trends Cell Biol 2001;11:188-9 (Pubitemid 32367867)
17. Gyrd-Hansen M, Darding M, Miasari M, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-KB as well as cell survival and oncogenesis. Nat Cell Biol 2008;10:1309-17
18. Gyrd-Hansen, et al. Identifed a ubiquitin-associated (UBA) domain in IAP proteins, which are evolutionary conserved and enable IAP proteins to bind to Lys-linked polyubiquitin.
19. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996;379:349-53 (Pubitemid 26033078)
20. Uren AG, Pakusch M, Hawkins CJ, et al. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci USA 1996;93:4974-8
21. Ma O, Cai WW, Zender L, et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplifed on chromosome 9, collaborate with p53 defciency in mouse osteosarcoma progression. Cancer Res 2009;69:2559-67
22. Vischioni B, van der Valk P, Span SW, et al. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 2006;37:78-86 (Pubitemid 41790506)
23. Young SS, Liston P, Xuan JY, et al. Genomic organization and physical map of the human inhibitors of apoptosis: HIAP1 and HIAP2. Mamm Genome 1999;10:44-8 (Pubitemid 29389942)
24. Conze DB, Albert L, Ferrick DA, et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol 2005;25:3348-56 (Pubitemid 40464334)
25. Cheung HH, Plenchette S, Kern CJ, et al. The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways. Mol Biol Cell 2008;19:2729-40
26. Mahoney DJ, Cheung HH, Mrad RL, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-KB activation. Proc Natl Acad Sci USA 2008;105:11778-83
27. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32
28. Kinzler KW, Nilbert MC, Su LK, et al. Identifcation of FAP locus genes from chromosome 5q21. Science 1991;253:661-5 (Pubitemid 21917199)
29. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9 (Pubitemid 21917200)
30. de la Chapelle A. Microsatellite instability. N Engl J Med 2003;349:209-10
31. Ponnelle T, Chapusot C, Martin L, et al. Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. Pathol Res Pract 2003;199:723-31 (Pubitemid 38016417)
32. Endo T, Abe S, Seidlar HB, et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother 2004;53:770-6 (Pubitemid 39149903)
33. Krajewska M, Kim H, Kim C, et al. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 2005;11:5451-61 (Pubitemid 41060821)
34. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic signifcance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803 (Pubitemid 30305074)
35. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999;93:3601-9 (Pubitemid 29249804)
36. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57
37. Huerta S, Goulet EJ, Livingston EH. Colon cancer and apoptosis. Am J Surg 2006;191:517-26 (Pubitemid 43384150)
38. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-6
39. Greco C, Alvino S, Buglioni S, et al. Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression. Anticancer Res 2001;21:3185-92 (Pubitemid 34224216)
40. Fridman JS, Rehemtulla A, Hofmann A, et al. Expression of Bcl-XS alters cytokinetics and decreases clonogenic survival in K12 rat colon carcinoma cells. Oncogene 1998;17:2981-91 (Pubitemid 29012201)
41. Krammer PH. CD95/s deadly mission in the immune system. Nature 2000;407:789-95
42. Adrain C, Martin SJ. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem Sci 2001;26:390-7 (Pubitemid 32530658)
43. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-23 (Pubitemid 28171907)
44. Chauhan D, Hideshima T, Rosen S, et al. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001;276:24453-6
45. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42
46. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005;11:3155-62 (Pubitemid 40627860)
47. Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006;81:824-31 (Pubitemid 44682183)
48. Sun Y, Ottosson A, Pervaiz S, Fadeel B. Smac-mediated sensitization of human B-lymphoma cells to staurosporine-and lactacystin-triggered apoptosis is apoptosome-dependent. Leukemia 2007;21:1035-43 (Pubitemid 46672081)
49. Santoro MM, Samuel T, Mitchell T, et al. Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet 2007;39:1397-402 (Pubitemid 350035006)
50. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFalpha-dependent apoptosis. Cell 2007;131:669-81 (Pubitemid 350087204)
51. Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689-700 (Pubitemid 351818251)
52. Rothe M, Pan MG, Henzel WJ, et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995;83:1243-52 (Pubitemid 26007814)
53. Chu ZL, McKinsey TA, Liu L, et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci USA 1997;94:10057-62 (Pubitemid 27406993)
54. Dejardin E. The alternative NF-κB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 2006;72:1161-79 (Pubitemid 44479741)
55. Swinney DC, Xu YZ, Scarafa LE, et al. A small molecule ubiquitination inhibitor blocks NF-KB-dependent cytokine expression in cells and rats. J Biol Chem 2002;277:23573-81 (Pubitemid 34952193)
56. Satoh T, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009;15:3872-80
57. Iwai M, Minematsu T, Narikawa S, et al. Involvement of human organic cation transporter 1 (OCT1) in the hepatic uptake of YM155 monobromide, 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-naphtho2,3-d]imidazolium bromide, a novel, small molecule survivin suppressant. Drug Metab Dispos 2009;37:1856-63
58. Minematsu T, Iwai M, Sugimoto K, et al. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-naphtho2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos 2009;37:619-28
59. Wu G, Chai J, Suber TL, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000;408:1008-12 (Pubitemid 32101651)
60. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL-and TNFalpha-mediated cell death. Science 2004;305:1471-4 (Pubitemid 39167668)
61. Sun W, Nikolovska-Coleska Z, Qin D, et al. Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. J Med Chem 2009;52:593-6
62. Zobel K, Wang L, Varfolomeev E, et al. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006;1:525-33
63. Lu J, Bai L, Sun H, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008;68:9384-93
64. Sun H, Nikolovska-Coleska Z, Lu J, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 2007;129:15279-94 (Pubitemid 350247811)
65. Peng Y, Sun H, Nikolovska-Coleska Z, et al. Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. J Med Chem 2008;51:8158-62
66. Friboulet L, Pioche-Durieu C, Rodriguez S, et al. Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 2008;10:1183-94
67. Cossu F, Milani M, Mastrangelo E, et al. Structural basis for bivalent smac-mimetics recognition in the IAP protein family. J Mol Biol 2009, published online 22 April 2009, doi:10.1016/j.jmb.2009.04.033
68. Galban S, Hwang C, Rumble JM, et al. Cytoprotective effects of IAPs revealed by a small molecule antagonist. Biochem J 2009;417:765-71
69. LaCasse EC, Mahoney DJ, Cheung HH, et al. IAP-targeted therapies for cancer. Oncogene 2008;27:6252-75
70. LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006;12:5231-41 (Pubitemid 44453353)
71. Rodel F, Frey B, Leitmann W, et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71:247-55 (Pubitemid 351491424)
72. Silasi DA, Alvero AB, Rutherford TJ, et al. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother 2009;10:1059-67
73. Saif MW, Tytler E, Lansigan F, et al. Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opin Investig Drugs 2009;18:469-79
74. Ishikawa C, Tafuku S, Kadekaru T, et al. Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Int J Cancer 2008;123:2702-12